Date: 2017-05-09
Type of information: Nomination
Compound:
Company: Kymab (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 9, 2017, Kymab announced the appointment of Dr Sonia Quaratino as its first Chief Medical Officer.
- Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio. She is an immunologist and joins Kymab from Novartis, where she has served as Global Clinical Program Leader – Transitional Clinical Oncology, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology. Prior to her role with Novartis, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators. Dr Quaratino also has over 20 years of professional experience in biomedical research in UK academic institutions including Imperial College London and the University of Southampton.
Financial terms:
Latest news:
Is general: Yes
